PubMed · 2005 · 13 citations · 11 references
Life SciencesGeneticsMolecular GeneticsCancer GeneticsGenetic EpidemiologyMedical GeneticsGenetic Risk AssessmentGenitourinary Cancer EpidemiologyGermline Cancer SusceptibilityProstate CancerVariant InterpretationCancer Risk AssociationDisease RiskFamilial Cancer RiskGenetic Susceptibility To Prostate CancerHereditary Cancer RiskInherited Cancer RiskSusceptibility Gene FunctionTumor Susceptibility Genes
BACKGROUND: A thymidine to cytosine transition (designated A2 variant) in the promoter region of CYP17 has previously been associated with a familial history of prostate cancer in North American families. The purpose of the present study was to determine whether this correlation could be replicated in a European population. MATERIALS AND METHODS: Case-control comparisons were performed by modelling a dominant (A1/A2 + A2/A2 vs. A1/A1) and a recessive (A2/A2 vs. A1/A2 + A1/A1) effect of the promoter modification. RESULTS: An insignificant overrepresentation of homozygous carriers of the A2 allele (recessive effect) was found in sporadic cases, as compared to controls. However, the A2 variant was not related to familial disease. CONCLUSION: Our results do not suggest a role of CYP17 as a high-risk susceptibility gene for familial prostate cancer, nor as a modifier for the disease risk in the European population.
11
Mendelian inheritance of familial prostate cancer.
B S Carter, Terri H. Beaty, Gary D. Steinberg et al. · Proceedings of the National Academy of Sciences · 1992 · 786 citations
Life Sciences, Genetics, Oncology +17
Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2)
Ruth M. Lunn, Douglas A. Bell, James L. Mohler et al. · Carcinogenesis · 1999 · 209 citations · Full text
A polymorphism in theCYP17 gene is associated with prostate cancer risk
Andrea Gsur, Gabriele Bernhofer, Sonja Hinteregger et al. · International Journal of Cancer · 2000 · 126 citations
Medicine, Endocrinology, Genetics +15